AVALO THERAPEUTICS, INC. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AVALO THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2021-12-31 was $8.61M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2021-09-30 was -$8.61M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2021-06-30 was $0.00.
- AVALO THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2021-03-31 was $37.65M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, other for fiscal 2021 was $37.65M.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2021-12-31 | $8.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $37.65M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$8.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | |
| 2021-03-31 | $37.65M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |